WO1997005870A3 - Use of griseofulvin for inhibiting the growth of cancers - Google Patents

Use of griseofulvin for inhibiting the growth of cancers Download PDF

Info

Publication number
WO1997005870A3
WO1997005870A3 PCT/US1996/012475 US9612475W WO9705870A3 WO 1997005870 A3 WO1997005870 A3 WO 1997005870A3 US 9612475 W US9612475 W US 9612475W WO 9705870 A3 WO9705870 A3 WO 9705870A3
Authority
WO
WIPO (PCT)
Prior art keywords
griseofulvin
cancers
inhibiting
growth
conjunction
Prior art date
Application number
PCT/US1996/012475
Other languages
French (fr)
Other versions
WO1997005870A2 (en
Inventor
James Berger Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SK142-98A priority Critical patent/SK14298A3/en
Priority to JP9508495A priority patent/JPH11511136A/en
Priority to IL13301499A priority patent/IL133014A0/en
Priority to BR9609920A priority patent/BR9609920A/en
Priority to AU66834/96A priority patent/AU713031B2/en
Priority to IL12309496A priority patent/IL123094A0/en
Application filed by Procter & Gamble filed Critical Procter & Gamble
Priority to HU9903506A priority patent/HUP9903506A3/en
Priority to EP96926807A priority patent/EP0841914A2/en
Priority to MX9800945A priority patent/MX9800945A/en
Publication of WO1997005870A2 publication Critical patent/WO1997005870A2/en
Publication of WO1997005870A3 publication Critical patent/WO1997005870A3/en
Priority to NO980420A priority patent/NO980420L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A pharmaceutical composition for the treatment of cancers or tumors in mammals is disclosed which comprises griseofulvin. A chemotherapeutic agent can be used in conjunction with griseofulvin as can potentiators. Griseofulvin can also be used to treat viral infections, either alone, in conjunction with other viral agents or with a potentiator.
PCT/US1996/012475 1995-08-03 1996-07-30 Use of griseofulvin for inhibiting the growth of cancers WO1997005870A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP9508495A JPH11511136A (en) 1995-08-03 1996-07-30 Use of griseofulvin to inhibit cancer growth
IL13301499A IL133014A0 (en) 1995-08-03 1996-07-30 Pharmaceutical compositions containing griseofulvin for treating viral infections
BR9609920A BR9609920A (en) 1995-08-03 1996-07-30 Use of griseofulvin to inhibit cancer growth
AU66834/96A AU713031B2 (en) 1995-08-03 1996-07-30 Use of griseofulvin for inhibiting the growth of cancers
IL12309496A IL123094A0 (en) 1995-08-03 1996-07-30 Pharmaceutical compositions containing griseofulvin for inhibiting the growth of cancers
SK142-98A SK14298A3 (en) 1995-08-03 1996-07-30 Use of griseofulvin for inhibiting the growth of cancers
HU9903506A HUP9903506A3 (en) 1995-08-03 1996-07-30 Use of griseofulvin for inhibiting the growth of cancers
EP96926807A EP0841914A2 (en) 1995-08-03 1996-07-30 Use of griseofulvin for inhibiting the growth of cancers
MX9800945A MX9800945A (en) 1995-08-03 1996-07-30 Use of griseofulvin for inhibiting the growth of cancers.
NO980420A NO980420L (en) 1995-08-03 1998-01-30 Use of griseofulvin to inhibit cancer growth

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US183995P 1995-08-03 1995-08-03
US67418196A 1996-07-16 1996-07-16
US08/674,181 1996-07-16
US60/001,839 1996-07-16

Publications (2)

Publication Number Publication Date
WO1997005870A2 WO1997005870A2 (en) 1997-02-20
WO1997005870A3 true WO1997005870A3 (en) 1997-04-17

Family

ID=26669547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/012475 WO1997005870A2 (en) 1995-08-03 1996-07-30 Use of griseofulvin for inhibiting the growth of cancers

Country Status (16)

Country Link
EP (1) EP0841914A2 (en)
JP (1) JPH11511136A (en)
KR (1) KR19990036137A (en)
AR (1) AR003176A1 (en)
AU (1) AU713031B2 (en)
BR (1) BR9609920A (en)
CA (1) CA2228503A1 (en)
CZ (1) CZ30598A3 (en)
HU (1) HUP9903506A3 (en)
IL (1) IL123094A0 (en)
MX (1) MX9800945A (en)
NO (1) NO980420L (en)
PL (1) PL324905A1 (en)
SK (1) SK14298A3 (en)
TR (1) TR199800244T2 (en)
WO (1) WO1997005870A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
DK1098641T3 (en) * 1998-07-27 2016-08-15 St Jude Pharmaceuticals Inc Chemically induced intracellular hyperthermia
AU761844C (en) 1998-11-09 2004-09-23 F. Hoffmann-La Roche Ag Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
CN1543356B (en) * 2001-06-25 2011-09-28 味之素株式会社 Anti-tumor agent
EP2008652A1 (en) * 2007-06-28 2008-12-31 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
EP2204367A1 (en) 2008-12-22 2010-07-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
E. HUANT: "Premières expérimentations cliniques de l'activité anti-mitotique de la griséofulvine en thérapeutique antitumorale.", THERAPIE, vol. 22, no. 5, 1967, pages 1143 - 1151, XP000617126 *

Also Published As

Publication number Publication date
AU6683496A (en) 1997-03-05
KR19990036137A (en) 1999-05-25
SK14298A3 (en) 1998-09-09
HUP9903506A2 (en) 2000-06-28
IL123094A0 (en) 1998-09-24
AU713031B2 (en) 1999-11-18
NO980420L (en) 1998-04-03
CA2228503A1 (en) 1997-02-20
TR199800244T2 (en) 1998-09-21
NO980420D0 (en) 1998-01-30
WO1997005870A2 (en) 1997-02-20
MX9800945A (en) 1998-04-30
AR003176A1 (en) 1998-07-08
EP0841914A2 (en) 1998-05-20
HUP9903506A3 (en) 2000-07-28
PL324905A1 (en) 1998-06-22
BR9609920A (en) 1999-07-06
JPH11511136A (en) 1999-09-28
CZ30598A3 (en) 1998-06-17

Similar Documents

Publication Publication Date Title
WO1997005870A3 (en) Use of griseofulvin for inhibiting the growth of cancers
WO2001016136A3 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
MY122771A (en) Heterocyclically substituted benzimidazoles, their preparation and use thereof
UA39158C2 (en) derivatives of N4-oxycarbonyl- 5'-deoxy-5-fluorocytidine and pharmaceutical preparation based thereon
CA2292359A1 (en) Novel azalides and methods of making same
NZ507350A (en) Semi-synthetic ecteinascidins and use in treatment of tumors
AU1392900A (en) 2,5-diazabicyclo(2.2.1)heptane derivatives, their preparation and therapeutic uses
BG103947A (en) Derivatives of 9-oxymerythromycin
WO1997005873A3 (en) Use of fluconazole for inhibiting the growth of cancers
HUP0204449A3 (en) Oncolytic combinations for the treatment of cancer, containing 2',2'-difluoronucleoside and leukotriene antagonist as active ingredients
WO1993000094A3 (en) Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
WO2001034198A3 (en) Oncolytic combinations for the treatment of cancer
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
AU1916501A (en) Oncolytic combinations for the treatment of cancer
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
WO2001046178A3 (en) Substituierte bisindolymaleimide
CA2410160A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents
AU1595001A (en) Oncolytic combinations for the treatment of cancer
AU1917101A (en) Oncolytic combinations for the treatment of cancer
WO2001034134A3 (en) Oncolytic combinations for the treatment of cancer
EP1889624A3 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
WO1996025400A3 (en) 3-aromatic and 3-heteroaromatic substituted bisnaphthalimides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2228503

Country of ref document: CA

Ref document number: 2228503

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1998-305

Country of ref document: CZ

Ref document number: 14298

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 1997 508495

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/000945

Country of ref document: MX

Ref document number: 1019980700805

Country of ref document: KR

Ref document number: 315185

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1996926807

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1199800130

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 1998/00244

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1996926807

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1998-305

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019980700805

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 2000705213

Country of ref document: KR

Kind code of ref document: A

WWW Wipo information: withdrawn in national office

Ref document number: 1996926807

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019980700805

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1998-305

Country of ref document: CZ